News | May 23, 2014

Stentys Sirolimus-Eluting Stent Demonstrates Efficacy for Heart Attack Patients

May 23, 2014 — Stentys presented final results from the APPOSITION IV study of its new self-apposing sirolimus-eluting stent (SES) during the Hotline session at the EuroPCR conference in Paris.

APPOSITION IV enrolled 152 patients experiencing ST-elevation myocardial infarction (STEMI) and was the first clinical trial to evaluate the self-apposing sirolimus-eluting stent, which was compared to Medtronic’s Resolute zotarolimus-eluting stent at two different time points, four and nine months. The evaluation was based on two imaging modalities: quantitative coronary angiography (QCA) to measure the difference in artery diameters between implantation and follow-up, and optical coherence tomography (OCT) to quantify the number of stent struts apposed and “covered” by tissue, an indication that the endothelial cells lining the artery wall have grown around the stent and that the vessel has healed.

At nine months, the Stentys SES showed no reduction in artery lumen diameter (late lumen loss of 0.04mm ± 0.43 under QCA) with a near perfect arterial healing (99 percent covered struts at nine months under OCT), demonstrating stent efficacy and safety.

Stent apposition was statistically better in the Stentys group than the balloon-expandable group at four months (0.07 percent malapposed struts vs 1.16 percent, p=0.005), and a greater percentage of Stentys stents were fully covered (33 percent vs. 4 percent, p=0.02). At nine months, strut apposition and coverage were similar in both groups. The results confirm that arteries with Stentys SES healed faster than with balloon-expandable drug-eluting stents (DES).

"In the APPOSITION IV trial, we found that the addition of sirolimus elution to the Stentys platform brings the best of both worlds together for heart attack patients,” said Robert-Jan van Geuns, M.D., Ph.D., Erasmus Medical Center, Rotterdam, the Netherlands, co-principal investigator. “An efficacious drug with a perfectly apposed stent over time ensures fast healing and an open vessel in the long run."

"We are thrilled with the results and very grateful to the APPOSITION IV study investigators for further advancing the knowledge and clinical experience of the self-apposing technology," said Gonzague Issenmann, CEO and co-founder of Stentys. "With these study results, our sirolimus-eluting stent could receive CE mark as soon as the second half of this year."

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init